The main aim of this seminar was to promote the exchange of knowledge and the interaction between basic scientists and clinicians as well as between the different research groups that are currently working on targeted therapy of lung cancer. The participants evaluated advance in lung-cancer targeted therapy so far and defined topics of future research projects aimed to improve the efficacy of targeted drugs as well as their availability to larger subgroups of lung cancer patients.
Molecular abnormalities and histopathology in lung cancer
Philipp Schnabel (Homburg/Saar, Germany)
|  |
How to get the tissue for which issues?
Fernando Gamarra (Munich, Germany)
| |
Liquid biopsy as an alternative
Rafael Rosell (Badalona, Spain)
|  |
Tyrosine Kinase Transmembrane Receptor alterations in NSCLC
Nicolas Girard (Lyon, France)
| |
EGFR TKI in the current clinical practice
Jacques Cadranel (Paris, France)
| |
Failure of EGFR TKI treatment: mechanisms and current strategies?
Rafael Rosell (Badalona, Spain)
| |
Target other gene point mutations: HER2 and rare EGFR mutations
Federico Cappuzzo (Livorno, Italy)
| |
Target gene rearrangements: ALK, ROS and RET
Luis Paz-Ares (Seville, Spain)
| |
Target amplification/protein surexpression: c met and FGFR
Nicolas Girard (Lyon, France)
| |
What have we learn from rebiospy studies?
Anne-Pascale Meert (Brussels, Belgium)
| |
What can we learn from animal models?
Christine Lovly (Nashville, United States of America)
| |
What could we learn from ongoing therapeutic trials?
David Planchard (Roussy-Villejuif, France)
| |
Optimizing the target therapy development
Jacques Cadranel (Paris, France)
| |
Ongoing studies
Thierry Berghmans (Brussels, Belgium)
| |